Akeso (FRA:4RY) Tariff Resilience Score: 7/10 (As of Jul. 05, 2026)


FRA:4RY Akeso Inc FRA:4RY
54 GF Score
Price €11.28
GF Value €15.94
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Akeso Tariff Resilience Score?

Akeso FRA:4RY +6.67% 54 Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus rates FRA:4RY with a GF Score™ of 54/100 and a GF Value™ of €15.94 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,369 Biotechnology companies, Akeso ranks better than 90.36% on this metric.

Akeso has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Akeso has Biopharmaceutical company with some exposure to tariffs on raw materials and equipment. Strong domestic market focus and potential for alternative suppliers enhance resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Akeso might have Highly Resilient.

Akeso  (FRA:4RY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Akeso Tariff Resilience Score Related Terms

FRA:4RY vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Akeso's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Akeso's Tariff Resilience Score falls into.


FRA:4RY
54GF Score
Akeso Inc FRA:4RY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Akeso (FRA:4RY) has a Tariff Resilience Score of 7 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Akeso ranks #132 out of 1369 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Akeso's Tariff Resilience Score too high?
Akeso's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Akeso's value of 7 is 75% above this industry median. Based on the distribution chart, Akeso ranks #132 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Akeso has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akeso's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Akeso ranks #132 out of 1369 companies for Tariff Resilience Score. This places Akeso in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Akeso's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akeso's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akeso's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.94, compared to a current price of €11.28 — trading 29.2% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Akeso's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Akeso (FRA:4RY), the current Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akeso (FRA:4RY) Overvalued in 2026?

Based on GuruFocus' analysis, Akeso stock appears to be undervalued. The current stock price of €11.28 is trading 29.2% below its estimated GF Value™ of €15.94. GuruFocus considers Akeso to be Modestly Undervalued.

Key valuation signals for FRA:4RY:

  • Tariff Resilience Score: 7
  • GF Value™: €15.94 vs. price of €11.28 (29.2% below fair value)
  • GF Score™: 54/100 with 5 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1369)

No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akeso Business Description

Address No. 6, Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
54GF Score

Get the complete analysis for FRA:4RY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.28
Price
€15.94
GF Value